Loading stock data…
OVID
$2.79+0.02 (+0.72%)
Market ClosedLast close May 1
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ovid Therapeutics Inc. in the Healthcare sector is trading at $2.79. The stock is currently near its 52-week high of $3.10, remaining 75.5% above its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why OVID maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.79
Potential Upside
5%
Whystock Fair Value$2.93
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a G...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$463.74M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.03
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-52.55%
Volume
Today's trading volume
950,794
Recent News
Ovid Therapeutics Q4 Earnings Call Highlights
Ovid Therapeutics (NASDAQ:OVID) outlined new pipeline and financing updates alongside its fourth-quarter and full-year 2025 results, highlighting regulatory clearance in Australia for its KCC2 direct activator OV4071, new safety and tolerability data for its seizure candidate OV329, and a $60 millio
Here's Why Ovid Therapeutics Stock Popped Higher Today
Ovid stock surged 18% following positive Phase 1 data for OV329, and investors are getting excited about a forthcoming Phase 2.
Exchange-Traded Funds, Equity Futures Lower Ahead of Key Economic Data, FOMC Meeting
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.3% and the actively tr
Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +158.71% and +195.47%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates
Niagen Bioscience (NAGE) delivered earnings and revenue surprises of +100.00% and +8.81%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?